AP NEWS
Click to copy
Press release content from Business Wire. The AP news staff was not involved in its creation.
Click to copy
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

New KEDRAB® Dose Calculator Launches to Help Hospitals in Treating Rabies Exposures

August 7, 2019

FORT LEE, N.J.--(BUSINESS WIRE)--Aug 7, 2019--

The KEDRAB ® Dose Calculator launched today, at the height of rabies season in the U.S., and will help healthcare providers in treating rabies exposures. KEDRAB [Rabies Immune Globulin (Human)] is a human rabies immunoglobulin (HRIG) indicated for post-exposure prophylaxis (PEP) of rabies infection. Administered concurrently with a full course of rabies vaccine, HRIG is an important component of rabies post-exposure prophylaxis (PEP) for previously unvaccinated persons. PEP is a highly effective treatment regimen issued by the U.S. Centers for Disease Control and Prevention and the Advisory Committee on Immunization Practices (ACIP).

The KEDRAB ® Dose Calculator, created by Kedrion Biopharma, is a free, easy-to-use online tool that prompts healthcare providers to input the weight of a patient who has been exposed to rabies. Then, the tool immediately calculates the precise KEDRAB dose needed. Rabies is almost always fatal when left untreated. However, by administering rabies post-exposure prophylaxis (PEP) promptly and properly, healthcare professionals can prevent the onset of rabies symptoms. PEP, when administered according to ACIP guidelines, is essentially 100 percent effective in preventing human rabies.

“Rabies is a medical urgency and care should not be delayed. Because rabies is a fatal disease, there is no room for treatment error when a person exposed to rabies presents at the emergency room or clinic,” said Peter Costa, MPH, MCHES, AVES (Hon), Rabies Immunoglobulin Brand Director. “The KEDRAB ® Dose Calculator was created to help clinicians quickly and accurately dose KEDRAB, which is a critical component of the rabies post-exposure prophylaxis regimen.”

About KEDRAB ®

KEDRAB ® [Rabies Immune Globulin (Human)] is a human rabies immunoglobulin (HRIG) manufactured by Kamada Ltd. and distributed by Kedrion Biopharma, indicated for passive, transient post-exposure prophylaxis (PEP) of rabies infection, when given promptly after contact with a rabid or possibly rabid animal. KEDRAB should be administered concurrently with a full course of rabies vaccine.

Important Safety Information

About Rabies

Rabies is a preventable viral disease of mammals most often transmitted through the bite of a rabid animal. It is a serious, and nearly always fatal, infection. In the U.S., rabies in wild animals, especially raccoons, skunks, foxes, coyotes and bats, accounts for most cases of rabies passed on to humans, pets, and other domestic animals. An acute, progressive viral encephalomyelitis, rabies carries the highest case fatality rate of any conventional etiological agent. Rabies is one of the oldest described infectious diseases, known for over 5,000 years.

About Kedrion Biopharma

Kedrion Biopharma is an international company that collects and fractionates blood plasma to produce and distribute plasma-derived therapeutic products for use in treating and preventing serious diseases, disorders and conditions such as hemophilia, primary immune system deficiencies and Rh-sensitization. Kedrion Biopharma Inc., the U.S. subsidiary of Kedrion Biopharma, is headquartered in Fort Lee, New Jersey. Kedrion Biopharma launched US operations in 2011, but the company’s international roots stretch back several decades in the production of blood and plasma-derived products. Kedrion Biopharma places a high value on the welfare of those who benefit from its products, as well as on the people and the communities it serves. Additional information about Kedrion Biopharma can be found at www.kedrion.com and www.kedrion.us.

View source version on businesswire.com:https://www.businesswire.com/news/home/20190807005103/en/

CONTACT: Media:Forrest McCaleb

Director, Global Communications – U.S.

Kedrion Biopharma

f.mccaleb@kedrion.com

214-557-8030Sheila Burke

Method Health Communications

MethodHealthComms@gmail.com

484-667-6330

KEYWORD: NEW JERSEY UNITED STATES NORTH AMERICA

INDUSTRY KEYWORD: RESEARCH PUBLIC RELATIONS/INVESTOR RELATIONS MARKETING COMMUNICATIONS HEALTH GENERAL HEALTH SCIENCE

SOURCE: Kedrion Biopharma

Copyright Business Wire 2019.

PUB: 08/07/2019 07:00 AM/DISC: 08/07/2019 07:01 AM

http://www.businesswire.com/news/home/20190807005103/en

All contents © copyright 2019 The Associated Press. All rights reserved.